UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 12, 2016
Spotlight Innovation Inc. |
(Exact name of registrant as specified in its charter) |
Nevada | | 000-52542 | | 98-0518266 |
(State or other jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
6750 Western Parkway, Suite 200-226 West Des Moines, Iowa | | 50266 |
(Address of principal executive offices) | | (Zip Code) |
Registrant's telephone number, including area code: (515) 274-9087
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8 K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a 12 under the Exchange Act (17 CFR 240.14a 12)
¨ Pre commencement communications pursuant to Rule 14d 2(b) under the Exchange Act (17 CFR 240.14d 2(b))
¨ Pre commencement communications pursuant to Rule 13e 4(c) under the Exchange Act (17 CFR 240.13e 4(c))
Item 1.01 Entry into a Material Definitive Agreement.
Effective October 13, 2016, Spotlight Innovation Inc. (the “Company”) entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy.
Item 1.02 Termination of a Material Definitive Agreement.
On October 12, 2016 the Company entered into a Termination Agreement (the “Termination Agreement”) with Memcine Pharmaceuticals, Inc. (“Memcine”), the University of Iowa Research Foundation, and Dr. Tony Vanden Bush. Pursuant to the Termination Agreement the Company terminated and cancelled all of its interest in Memcine, terminated the shareholder agreement of Memcine, and John Krohn and Cristopher Grunewald resigned as officers and directors of Memcine.
Item 8.01 Other Events.
On October 14, 2016, the Company issued a Company Overview that it plans to present to potential and existing investors and that will be given at the Fall See Thru Equity Microcap Investor Conference in New York City on October 17, 2016. A copy of this Company Overview is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The Company Overview is also posted on the Company’s website, at www.spotlightinnovation.com/investors.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following documents are filed as Exhibits:
Exhibit | | Description |
| | |
10.34 | | Termination Agreement dated October 12, 2016 between Spotlight Innovation Inc. Memcine Pharmaceuticals, Inc., the University of Iowa Research Foundation, and Dr. Tony Vanden Bush. |
99.1 | | Company Overview dated October 2016.* |
________
*Furnished as an Exhibit pursuant to Item 8.01 hereof.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SPOTLIGHT INNOVATION INC. | |
| | | |
Dated: October 14, 2016 | By: | /s/ Cristopher Grunewald | |
| | Cristopher Grunewald, President and CEO | |
EXHIBIT INDEX
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following documents are filed as Exhibits:
Exhibit | | Description |
| | |
10.34 | | Termination Agreement dated October 12, 2016 between Spotlight Innovation Inc. Memcine Pharmaceuticals, Inc., the University of Iowa Research Foundation, and Dr. Tony Vanden Bush. |
99.1 | | Company Overview dated October 2016.* |
____________
*Furnished as an Exhibit pursuant to Item 8.01 hereof.
